- Home
- AYTU vs SRFM Comparison
AYTU vs SRFM Comparison
Compare AYTU & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- SRFM
- Stock Information
- Founded
- AYTU N/A
- SRFM 2011
- Country
- AYTU United States
- SRFM United States
- Employees
- AYTU N/A
- SRFM N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- SRFM Transportation Services
- Sector
- AYTU Health Care
- SRFM Consumer Discretionary
- Exchange
- AYTU Nasdaq
- SRFM Nasdaq
- Market Cap
- AYTU 15.0M
- SRFM 15.0M
- IPO Year
- AYTU N/A
- SRFM 2023
- Fundamental
- Price
- AYTU $2.25
- SRFM $3.09
- Analyst Decision
- AYTU
- SRFM Hold
- Analyst Count
- AYTU 0
- SRFM 2
- Target Price
- AYTU N/A
- SRFM $2.50
- AVG Volume (30 Days)
- AYTU 31.2K
- SRFM 1.7M
- Earning Date
- AYTU 11-12-2024
- SRFM 11-12-2024
- Dividend Yield
- AYTU N/A
- SRFM N/A
- EPS Growth
- AYTU N/A
- SRFM N/A
- EPS
- AYTU N/A
- SRFM N/A
- Revenue
- AYTU $81,002,000.00
- SRFM $111,793,000.00
- Revenue This Year
- AYTU N/A
- SRFM $104.61
- Revenue Next Year
- AYTU N/A
- SRFM $53.30
- P/E Ratio
- AYTU N/A
- SRFM N/A
- Revenue Growth
- AYTU N/A
- SRFM 392.91
- 52 Week Low
- AYTU $2.16
- SRFM $0.90
- 52 Week High
- AYTU $3.50
- SRFM $11.83
- Technical
- Relative Strength Index (RSI)
- AYTU 39.00
- SRFM 65.59
- Support Level
- AYTU $2.26
- SRFM $1.68
- Resistance Level
- AYTU $2.44
- SRFM $2.77
- Average True Range (ATR)
- AYTU 0.14
- SRFM 0.28
- MACD
- AYTU -0.02
- SRFM 0.12
- Stochastic Oscillator
- AYTU 2.03
- SRFM 71.00
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.